EP3110455A4 - Behandlung von resistenten läsionen - Google Patents

Behandlung von resistenten läsionen Download PDF

Info

Publication number
EP3110455A4
EP3110455A4 EP15755058.3A EP15755058A EP3110455A4 EP 3110455 A4 EP3110455 A4 EP 3110455A4 EP 15755058 A EP15755058 A EP 15755058A EP 3110455 A4 EP3110455 A4 EP 3110455A4
Authority
EP
European Patent Office
Prior art keywords
treatment
resistant lesions
lesions
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15755058.3A
Other languages
English (en)
French (fr)
Other versions
EP3110455A2 (de
Inventor
Anthony Phillips
Scott BANNAN
Grove MATSUOKA
Bradford DUFT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocunexus Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of EP3110455A2 publication Critical patent/EP3110455A2/de
Publication of EP3110455A4 publication Critical patent/EP3110455A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15755058.3A 2014-02-25 2015-02-25 Behandlung von resistenten läsionen Withdrawn EP3110455A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944566P 2014-02-25 2014-02-25
PCT/US2015/017595 WO2015130840A2 (en) 2014-02-25 2015-02-25 Treatment of resistant lesions

Publications (2)

Publication Number Publication Date
EP3110455A2 EP3110455A2 (de) 2017-01-04
EP3110455A4 true EP3110455A4 (de) 2017-10-11

Family

ID=54009775

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15755058.3A Withdrawn EP3110455A4 (de) 2014-02-25 2015-02-25 Behandlung von resistenten läsionen

Country Status (3)

Country Link
EP (1) EP3110455A4 (de)
CA (1) CA2940648A1 (de)
WO (1) WO2015130840A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054724B2 (en) 2018-04-10 2024-08-06 President And Fellows Of Harvard College AAV vectors encoding clarin-1 or GJB2 and uses thereof
CN115103710A (zh) * 2019-09-30 2022-09-23 应用遗传科技公司 用于治疗遗传性听力损失的腺相关病毒(aav)系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2014145342A2 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Improved wound healing compositions and treatments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533515T1 (de) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulierungen enthaltend antisense nukleotide spezifisch für connexine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2014145342A2 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Improved wound healing compositions and treatments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID L. BECKER ET AL.: "Connexins in wound healing; perspectives in diabetic patients", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, vol. 1818, no. 8, 1 August 2012 (2012-08-01), AMSTERDAM, NL, pages 2068 - 2075, XP055307471, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2011.11.017 *
JOHANNA M. BRANDNER ET AL.: "Connexins 26, 30, and 43: Differences Among Spontaneous, Chronic, and Accelerated Human Wound Healing", 1 May 2004 (2004-05-01), XP055402063, Retrieved from the Internet <URL:http://ac.els-cdn.com/S0022202X15308010/1-s2.0-S0022202X15308010-main.pdf?_tid=93f36308-8cba-11e7-9b03-00000aab0f26&acdnat=1504012043_813c67923de0c385013b5614ac11fb7b> [retrieved on 20170829] *
MENDOZA-NARANJO ARIADNA ET AL.: "Targeting Cx43 and N-Cadherin, which are abnormally upregulated in Venous Leg Ulcers, influences migration, adhesion and activation of Rho GTPases", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 7, no. 5, 1 May 2012 (2012-05-01), pages e37374 - 1, XP002712338, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0037374 *

Also Published As

Publication number Publication date
WO2015130840A3 (en) 2015-11-05
EP3110455A2 (de) 2017-01-04
CA2940648A1 (en) 2015-09-03
WO2015130840A2 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
EP3212233A4 (de) Kombinationstherapie zur behandlung einer krankheit
EP3072436A4 (de) Endoskop
EP3078318A4 (de) Endoskop
EP3134436A4 (de) Behandlung von h-ras-gesteuerten tumoren
EP3097843A4 (de) Endoskop
EP3047788A4 (de) Endoskop
EP3157565A4 (de) Behandlung von polybakteriellen infektionen
EP3104880A4 (de) Verbesserte verfahren zur behandlung von vaskularisierenden karzinomen
EP3050488A4 (de) Endoskop
EP3183240A4 (de) Behandlung von gelenkerkrankungen
EP3175768A4 (de) Endoskop
EP3189333A4 (de) Krebsdiagnose
EP3205253A4 (de) Endoskop
EP3092940A4 (de) Endoskop
EP3106097A4 (de) Behandlungsinstrument
EP3138467A4 (de) Endoskop
EP3145931A4 (de) Behandlung von autoimmunerkrankungen
EP3096752A4 (de) Behandlung von neoplasien
EP3231347A4 (de) Endoskop
EP3158912A4 (de) Endoskop
EP3125937A4 (de) Behandlung von magenkrebs
EP3106112A4 (de) Behandlungsinstrument
GB201408297D0 (en) Treatment of cancer
EP3189767A4 (de) Endoskop
EP3130274A4 (de) Endoskop

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160923

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170907

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20170901BHEP

Ipc: A61K 48/00 20060101AFI20170901BHEP

Ipc: A61P 17/02 20060101ALI20170901BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OCUNEXUS THERAPEUTICS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OCUNEXUS THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180407